Amgen® Presence and Support | MVASI® (bevacizumab) | Amgen®

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

You are now leaving MVASI.EU and entering another Amgen website. Would you like to continue?

Stay on MVASI.EU Continue

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

AMGEN® PROVIDES THE SAME LEVEL OF SUPPORT FOR ITS BIOSIMILARS AS FOR ITS ORIGINATOR PRODUCTS

AMGEN® IS COMMITTED TO YOU AND YOUR PATIENTS

Patient journeys can be diverse. Amgen understands this and provides a host of services to support you, your care team, and your patients.
Amgen® has developed a robust patient education and support program* to help patients throughout their course of cancer treatment in having informed dialogues with their physician and care team, and to achieve the best possible outcomes.
Amgen®‘s patient education materials are available as a tool to help support the patients with their information needs about their treatment with MVASI®.

AMGEN® HAS A STRONG TRACK RECORD OF QUALITY MANUFACTURING AND RELIABLE DRUG SUPPLY1

> 99%
on time in full†1 deliveries from
2012-2017
  • All stock and supply for Europe is labelled and packaged in Europe1
  • Our 100-country manufacturing and distribution network ensures patients get the medicines they need1
  • Every unit adheres strictly to the same processes and quality-control measures
  • We invest heavily in risk mitigation on all levels to ensure supply and safety
  • Our customer service is available to assist you 24/7
* This program is only available in some countries. Reach out to your local Amgen team to identify if these resources are available in your country.
†Displayed as average OTIF from 2012-2017. On time and in full (OTIF) is an industry standard to measure order delivery performance to our customers. The remaining < 1% consist of returns & damaged products not resulting in interrupted supply or any patient impact.1

Reference:
  1. Schipper R, Middelkoop K, Biniass B, Hippenmeyer J. Assessment of drug supply reliability in Europe by evaluating on time in full (OTIF) delivery. Poster presented at BOPA 21st Annual Symposium 12–14 October 2018, Birmingham, UK.

Home